Legend Biotech Reports Third Quarter 2026 Results and Recent Highlights
Key Highlights
- ➤CARVYKTI net trade sales rose 36% year over year to approximately $710 million
- ➤Net income reached $51.7 million versus a $39.6 million net loss
- ➤Operating income reached $46.8 million versus a $43.3 million operating loss
- ➤LB2501 received U.S. FDA IND clearance for dual-targeting in vivo CAR-T therapy
- ➤Five-year data showed 10 of 20 patients alive and progression-free without further treatment
Expert Statements
Ingrid Zhang, Chief Executive Officer of Legend Biotech
“We made meaningful progress during the third quarter, expanding the reach of CARVYKTI and advancing our pipeline”
Ingrid Zhang, Chief Executive Officer of Legend Biotech
“Five-year CARTITUDE-2 Cohort A data added to the growing body of long-term evidence supporting the curative potential of CARVYKTI, especially in earlier-line multiple myeloma, demonstrating that half of the 20 patients remained alive and progression-free after a single infusion.”
Ingrid Zhang, Chief Executive Officer of Legend Biotech
“Together, the promising early line data and updated NCCN guidelines preferring CAR-T ahead of other BCMA-directed therapies well positions CARVYKTI to potentially gain market share in the second- and third-line setting.”
Ingrid Zhang, Chief Executive Officer of Legend Biotech
“We also achieved an important milestone for our next generation cell therapy pipeline with the IND clearance for LB2501.”
Ingrid Zhang, Chief Executive Officer of Legend Biotech
“We remain focused on disciplined execution, expanding access to CARVYKTI worldwide, advancing our innovative pipeline, and delivering sustained profitability.”
* CARVYKTI(®) (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 36% versus third quarter of 2025 to approximately $710 million * Half of CARTITUDE-2 Cohort A patients remained alive and progression-free without further anti-myeloma treatment five years after a single CARVYKTI(®) infusion, adding to growing long-term evidence supporting the curative potential of CARVYKTI in earlier-line RRMM * Updated NCCN Guidelines recommend that all patients with multiple myeloma be referred to a T-cell therapy capable center at first relapse for consideration of available therapies * Received U.S. FDA IND clearance for LB2501, an investigational CD19/CD20 dual-targeting in vivo CAR‑T therapy for relapsed or refractory B-cell malignancies * Appointed Ingrid Zhang as Chief Executive Officer * Cash and cash equivalents, and time deposits of approximately $853 million, as of September 30, 2026 BRIDGEWATER, N.J., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its third quarter 2026 unaudited financial results and recent highlights.
Get started
Create a free account to read the full story.